BOSTON, MA, uSA I October 20, 2015 I Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today that it will present data demonstrating GMP-synthesized single agent efficacy and a dose response in significantly reducing human muscle cramp intensity in its electrically induced cramp model at the Society for Neuroscience in Chicago, IL today at 2:00pm ET.
The abstract titled, “Transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin-1 (TRPA1) activators reduce human muscle cramping,” will be presented by Glenn Short, Ph.D., Senior Director of Research at Flex Pharma. An exploratory analysis of two concentrations of FLX-787, a GMP-synthesized single agent agonist of TRPA1 and TRPV1, demonstrated an increase in the human cramp inhibition effect size at the higher concentration consistent with significant dose-response efficacy (p<0.01).
“These results suggest that both the single agent molecules and the doublet combinations are efficacious at decreasing cramp intensity in a potentially dose-responsive manner,” said Tom Wessel, M.D., Flex Pharma Chief Medical Officer. “Along with the recent demonstration of enhanced efficacy with GMP-synthesized single agent and doublet combinations compared to the original proprietary formulation, our product development efforts continue to advance.”
“Taken together, these data demonstrate the utility of Flex Pharma’s proprietary products to treat cramps and the general strategy of chemical neuro stimulation to potentially limit alpha-motor neuron hyperexcitability in other neurological diseases,” commented Nobel laureate and Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair, Rod MacKinnon, M.D.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma’s proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Individuals can follow the Company on Twitter (@flexpharma) and the Company’s website (http://ir.flex-pharma.com/) to see the latest progress of the Company’s pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.
SOURCE: Flex Pharma
Post Views: 66
BOSTON, MA, uSA I October 20, 2015 I Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today that it will present data demonstrating GMP-synthesized single agent efficacy and a dose response in significantly reducing human muscle cramp intensity in its electrically induced cramp model at the Society for Neuroscience in Chicago, IL today at 2:00pm ET.
The abstract titled, “Transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin-1 (TRPA1) activators reduce human muscle cramping,” will be presented by Glenn Short, Ph.D., Senior Director of Research at Flex Pharma. An exploratory analysis of two concentrations of FLX-787, a GMP-synthesized single agent agonist of TRPA1 and TRPV1, demonstrated an increase in the human cramp inhibition effect size at the higher concentration consistent with significant dose-response efficacy (p<0.01).
“These results suggest that both the single agent molecules and the doublet combinations are efficacious at decreasing cramp intensity in a potentially dose-responsive manner,” said Tom Wessel, M.D., Flex Pharma Chief Medical Officer. “Along with the recent demonstration of enhanced efficacy with GMP-synthesized single agent and doublet combinations compared to the original proprietary formulation, our product development efforts continue to advance.”
“Taken together, these data demonstrate the utility of Flex Pharma’s proprietary products to treat cramps and the general strategy of chemical neuro stimulation to potentially limit alpha-motor neuron hyperexcitability in other neurological diseases,” commented Nobel laureate and Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair, Rod MacKinnon, M.D.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma’s proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Individuals can follow the Company on Twitter (@flexpharma) and the Company’s website (http://ir.flex-pharma.com/) to see the latest progress of the Company’s pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.
SOURCE: Flex Pharma
Post Views: 66
